截至9月30日，合锻智能股东户数7.80万，较上期增加10.01%；人均流通股6340股，较上期减少9.10%。 2025年1月-9月，合锻智能实现营业收入16.73亿元，同比增长14.03%；归母净利润-4432.77万元，同比 减少677.25%。 分红方面，合锻智能A股上市后累计派现1.57亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，合锻智能十大流通股东中，永赢睿信混合A（019431）位居第三 大流通股东，持股930.45万股，为新进股东。永赢稳健增强债券A（014088）位居第四大流通股东，持 股573.27万股，为新进股东。银华数字经济股票发起式A（015641）位居第六大流通股东，持股328.09 万股，为新进股东。信澳周期动力混合A（010963）位居第八大流通股东，持股211.14万股，为新进股 东。华夏高端制造混合A（002345）、华夏领先股票（001042）退出十大流通股东之列。 责任编辑：小浪快报 1月9日，合锻智能（维权）涨6.94%，成交额26.91亿元。两融数据显示，当日合锻智能获融资买入额 2.63亿元，融资偿还2.26亿元，融资净买入3710 ...

Group 1 - The core viewpoint of the news is that Kew Flower Pharmaceutical experienced a slight increase in stock price and trading volume, with notable changes in financing and stockholder dynamics [1][2] Group 2 - As of January 9, Kew Flower Pharmaceutical's stock price rose by 0.74%, with a trading volume of 37.18 million yuan. The financing buy-in amount was 2.92 million yuan, while the financing repayment was 2.43 million yuan, resulting in a net financing buy-in of 489,200 yuan [1] - The total financing and securities balance for Kew Flower Pharmaceutical reached 135 million yuan, with the financing balance accounting for 1.51% of the circulating market value, indicating a low level compared to the past year [1] - On the short-selling side, Kew Flower Pharmaceutical had a short-selling repayment of 100 shares and no short-selling sales, with a short-selling balance of 2.05 million yuan, which is above the 80th percentile level over the past year, indicating a high level [1] Group 3 - As of December 31, the number of shareholders for Kew Flower Pharmaceutical was 48,000, a decrease of 2.04% from the previous period, while the average circulating shares per person increased by 2.08% to 12,166 shares [2] - For the period from January to September 2025, Kew Flower Pharmaceutical reported a revenue of 1.684 billion yuan, a year-on-year decrease of 43.24%, and a net profit attributable to shareholders of -33.54 million yuan, a decrease of 105.72% year-on-year [2] - Since its A-share listing, Kew Flower Pharmaceutical has distributed a total of 4.045 billion yuan in dividends, with 1.752 billion yuan distributed in the last three years [2] Group 4 - As of September 30, 2025, among the top ten circulating shareholders of Kew Flower Pharmaceutical, E Fund CSI Dividend ETF ranked fifth with 3.4008 million shares, an increase of 239,600 shares from the previous period [2] - Hong Kong Central Clearing Limited ranked seventh with 2.8412 million shares, a decrease of 128,700 shares from the previous period [2] - The eighth largest circulating shareholder, China Merchants CSI Dividend ETF, held 2.8382 million shares, an increase of 234,900 shares, while the ninth largest, Southern CSI 1000 ETF, held 2.6757 million shares, a decrease of 20,300 shares [2]

Group 1 - On January 9, Shaanxi Coal Industry's stock increased by 0.49% with a transaction volume of 783 million yuan, while the financing net purchase was -44.38 million yuan, indicating a low financing balance compared to the past year [1] - As of September 30, 2025, Shaanxi Coal Industry reported a revenue of 118.08 billion yuan, a year-on-year decrease of 5.86%, and a net profit attributable to shareholders of 12.71 billion yuan, down 20.26% year-on-year [2] - The company has distributed a total of 81.64 billion yuan in dividends since its A-share listing, with 47.33 billion yuan distributed in the last three years [3] Group 2 - As of September 30, 2025, the number of shareholders of Shaanxi Coal Industry increased by 2.07% to 105,000, while the average circulating shares per person decreased by 2.02% to 92,312 shares [2] - Among the top ten circulating shareholders, China Securities Finance Corporation holds 195 million shares, unchanged from the previous period, while Hong Kong Central Clearing Limited reduced its holdings by 10.7 million shares to 133 million shares [3]

Group 1 - The core viewpoint of the news is that Zhonglai Co., Ltd. has shown significant trading activity and financial performance indicators, reflecting both challenges and opportunities in the solar energy sector [1][2]. Group 2 - On January 9, Zhonglai Co., Ltd. experienced a stock price increase of 0.56%, with a trading volume of 438 million yuan. The financing buy-in amount was 48.54 million yuan, while the financing repayment was 39.62 million yuan, resulting in a net financing buy of 8.92 million yuan [1]. - As of January 9, the total financing and securities lending balance for Zhonglai Co., Ltd. was 343 million yuan, with the financing balance accounting for 4.37% of the circulating market value, indicating a high level compared to the past year [1]. - The company reported a total revenue of 3.898 billion yuan for the period from January to September 2025, representing a year-on-year decrease of 14.21%. The net profit attributable to shareholders was -398 million yuan, a decline of 31.06% year-on-year [2]. - The company has distributed a total of 650 million yuan in dividends since its A-share listing, with 194 million yuan distributed over the past three years [2]. - As of September 30, 2025, the number of shareholders for Zhonglai Co., Ltd. was 49,900, a decrease of 6.15% from the previous period, while the average circulating shares per person increased by 6.56% to 19,172 shares [2].

1月9日，斯莱克涨0.39%，成交额3.17亿元。两融数据显示，当日斯莱克获融资买入额4692.21万元，融 资偿还6388.74万元，融资净买入-1696.53万元。截至1月9日，斯莱克融资融券余额合计7.19亿元。 融资方面，斯莱克当日融资买入4692.21万元。当前融资余额7.19亿元，占流通市值的7.10%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，斯莱克1月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量1.57万股，融券余额24.52万元，低于近一年10%分位水平，处于低位。 资料显示，苏州斯莱克精密设备股份有限公司位于江苏省苏州市吴中区胥口镇孙武路1028号，成立日期 2004年1月6日，上市日期2014年1月29日，公司主营业务涉及高速易拉盖、易拉罐等金属包装制品生产 设备的研发、设计、生产、装配调试,相关精密模具、智能检测设备、零备件的研发、加工制造等业 务。主营业务收入构成为：电池壳业务67.48%，易拉盖高速生产设备及系统改造11.43%，其他专用设 备及零备件8.87%，易拉罐高速生产设备及系统改造7.59%，光伏发电及其他3 ...

Group 1 - The core viewpoint of the news highlights the significant trading activity and financial performance of Hunan Silver, indicating a strong market presence and investor interest [1][2] - On January 9, Hunan Silver's stock price increased by 2.20%, with a trading volume of 1.736 billion yuan. The net financing purchase on that day was 60.86 million yuan, with a total financing balance of 920 million yuan, representing 5.00% of the circulating market value [1] - The company has a comprehensive production system and full industry chain layout, focusing on the mining, smelting, and deep processing of non-ferrous metals such as silver, lead, and zinc, with 99.87% of its revenue coming from non-ferrous metals and their products [1] Group 2 - As of September 30, the number of shareholders of Hunan Silver reached 153,400, an increase of 74.39% from the previous period, while the average circulating shares per person decreased by 43.11% [2] - For the period from January to September 2025, Hunan Silver achieved an operating income of 8.594 billion yuan, a year-on-year increase of 59.56%, and a net profit attributable to shareholders of 159 million yuan, up 28.44% year-on-year [2] - The company has distributed a total of 162 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]

Group 1 - On January 9, 2025, Liangxin Co., Ltd. saw a stock price increase of 5.75% with a trading volume of 748 million yuan [1] - The company had a financing buy-in amount of 101 million yuan and a net financing buy of 33.13 million yuan on the same day, with a total financing and margin balance of 376 million yuan [1] - The financing balance of Liangxin Co. represents 2.84% of its circulating market value and is above the 80th percentile of the past year, indicating a high level [1] Group 2 - As of September 30, 2025, Liangxin Co. had 39,400 shareholders, an increase of 21.36% from the previous period, while the average circulating shares per person decreased by 17.60% [2] - For the period from January to September 2025, Liangxin Co. achieved a revenue of 3.507 billion yuan, a year-on-year increase of 12.23%, while the net profit attributable to shareholders decreased by 2.08% to 304 million yuan [2] - The company has distributed a total of 1.986 billion yuan in dividends since its A-share listing, with 744 million yuan distributed in the last three years [2]

Group 1 - The core viewpoint of the news is that He Feng Co., Ltd. has shown a mixed performance in terms of stock trading and financial results, with a notable increase in revenue but a significant decline in net profit [1][2]. - On January 9, He Feng's stock rose by 0.83%, with a trading volume of 29.67 million yuan. The financing buy-in amount was 6.95 million yuan, while the net financing buy-in was 3.51 million yuan, indicating strong investor interest [1]. - As of January 9, the total balance of margin trading for He Feng was 173 million yuan, which is 2.60% of its circulating market value, indicating a high level of financing activity compared to the past year [1]. Group 2 - As of September 30, the number of shareholders for He Feng increased by 4.18% to 22,500, while the average circulating shares per person decreased by 4.01% to 40,474 shares [2]. - For the period from January to September 2025, He Feng reported a revenue of 28.07 billion yuan, reflecting a year-on-year growth of 16.92%. However, the net profit attributable to shareholders decreased by 55.34% to 129 million yuan [2]. - He Feng has distributed a total of 1.007 billion yuan in dividends since its A-share listing, with 158 million yuan distributed over the past three years [3].

融资方面，好利科技当日融资买入1364.54万元。当前融资余额1.58亿元，占流通市值的4.82%，融资余 额超过近一年80%分位水平，处于高位。 1月9日，好利科技（维权）涨9.99%，成交额2.34亿元。两融数据显示，当日好利科技获融资买入额 1364.54万元，融资偿还2244.07万元，融资净买入-879.54万元。截至1月9日，好利科技融资融券余额合 计1.58亿元。 资料显示，好利来(中国)电子科技股份有限公司位于福建省厦门市翔安区舫山东二路829号，成立日期 1992年5月23日，上市日期2014年9月12日，公司主营业务涉及熔断器、自复保险丝等过电流、过热电路 保护元器件的研发、生成和销售。主营业务收入构成为：电力熔断器及配件64.28%，电子熔断器及配 件32.25%，其他(补充)3.46%。 截至9月30日，好利科技股东户数2.20万，较上期减少10.75%；人均流通股7978股，较上期增加 12.05%。2025年1月-9月，好利科技实现营业收入3.22亿元，同比增长16.75%；归母净利润3899.14万 元，同比增长14.35%。 融券方面，好利科技1月9日融券偿还0.00股，融券卖 ...

Group 1 - The core viewpoint of the news is that Jiukang Bio's stock performance and financial metrics indicate a challenging period, with a notable decline in revenue and net profit year-on-year [2][3] - On January 9, Jiukang Bio's stock rose by 0.59%, with a trading volume of 87.04 million yuan, and a net financing buy of -2.81 million yuan, indicating a higher level of financing compared to the past year [1] - As of January 9, the total margin balance for Jiukang Bio was 195 million yuan, accounting for 2.45% of its market capitalization, which is above the 70th percentile of the past year [1] Group 2 - As of September 30, the number of Jiukang Bio's shareholders decreased by 2.48% to 18,100, while the average circulating shares per person increased by 2.54% to 23,502 shares [2] - For the period from January to September 2025, Jiukang Bio reported a revenue of 1.012 billion yuan, a year-on-year decrease of 18.24%, and a net profit attributable to shareholders of 272 million yuan, down 27.03% year-on-year [2] - Jiukang Bio has distributed a total of 1.33 billion yuan in dividends since its A-share listing, with 701 million yuan distributed over the past three years [3]